Latest news with #EU5
Globe and Mail
02-07-2025
- Business
- Globe and Mail
Idiopathic Membranous Nephropathy Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Prevalence, Statistics, Revenue, Therapies, Companies by DelveInsight
"Idiopathic Membranous Nephropathy Market" Idiopathic Membranous Nephropathy companies include Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astellas Pharma Inc., Baxter Healthcare Corporation, Sigma Aldrich Corporation, and others. (Albany, USA) DelveInsight's " Idiopathic Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Complicated Urinary Tract Infection (cUTI), historical and forecasted epidemiology as well as the Complicated Urinary Tract Infection (cUTI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Idiopathic Membranous Nephropathy market growth is driven by factors like increase in the prevalence of Idiopathic Membranous Nephropathy, investments in research and development, entry of emerging therapies during the study period 2020-2034. The Idiopathic Membranous Nephropathy market report also offers comprehensive insights into the Idiopathic Membranous Nephropathy market size, share, Idiopathic Membranous Nephropathy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Idiopathic Membranous Nephropathy market size growth forward. Some of the key highlights from the Idiopathic Membranous Nephropathy Market Insights Report: The Idiopathic Membranous Nephropathy market size in the 7MM is expected to reach ~USD 1,000 million by 2034. Several key pharmaceutical companies, including Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astellas Pharma Inc., Baxter Healthcare Corporation, Sigma Aldrich Corporation, and others, are developing novel products to improve the Idiopathic Membranous Nephropathy treatment outlook. In 2023, the United States represented around 40% of all prevalent cases of Idiopathic Membranous Nephropathy across the 7MM. Data from Japan indicates that the prevalence of Idiopathic Membranous Nephropathy is expected to remain relatively stable from 2024 to 2034. Among the EU4 countries and the UK, Germany had the highest prevalence of the condition, accounting for about 30% of cases, followed by the UK with approximately 20% in 2023. In the same year, PLA2R-specific cases in the EU4 and the UK made up about 75% of the total cases in the 7MM. The market for Idiopathic Membranous Nephropathy (IMN) across the 7MM is projected to reach approximately USD 1,000 million by 2034. In 2023, the United States holds the largest market share, with around USD 88 million, compared to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. IMN is a major type of glomerular disease, marked by high protein levels in the urine (nephrotic syndrome) and is primarily autoimmune in nature. Currently, there are no specific approved treatments for IMN, and management mainly involves supportive care. The market is expected to experience significant growth due to the increased use of existing drugs, the anticipated launch of new therapies, and growing awareness. The total number of prevalent IMN cases in the 7MM is estimated to be about 71,000 in 2023. Of these, the US represents approximately 40% of the cases, while the EU4 and the UK together account for around 35%, and Japan contributes roughly 25%, making Japan the second-largest contributor after the US. Several promising drugs in the pipeline include TNT119, ALPN-303, MOR202, SNP-ACTH (1-39) Gel, and GAZYVA. In December 2024, SynAct Pharma Aps announced results of an Exploratory, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AP1189 Versus Placebo Administered for 12 Weeks as an add-on to Patients, in ACE Inhibitor or Angiotensin II Receptor Blocker Treatment, With Idiopathic Membranous Nephropathy and Severe Proteinuria In October 2023, Human Immunology Biosciences (HI-Bio) received FDA's Breakthrough Therapy designation for felzartamab to treat primary membranous nephropathy. In June 2023, the FDA granted orphan drug designation to SNP-ACTH (1-39) gel for primary membranous nephropathy. Additionally, Biogen completed its acquisition of HI-Bio in July 2024. In June 2022, HI-Bio and MorphoSys AG entered into a licensing agreement for the development and commercialization of MorphoSys' anti-CD38 antibody, felzartamab. In the 7MM, MOR202 (felzartamab) is projected to generate the highest market revenue, reaching around USD 500 million by 2034. Within the EU4 and the UK, Germany had the largest market size, totaling approximately USD 10 million in 2023. As per DelveInsight analysis, the Idiopathic Membranous Nephropathy market is anticipated to witness growth at a considerable CAGR Idiopathic Membranous Nephropathy Overview Idiopathic Membranous Nephropathy (IMN) is a common form of glomerular disease primarily linked to nephrotic syndrome. It occurs when the immune system attacks the glomeruli, resulting in significant protein loss in the urine, swelling, and the potential for kidney failure. The condition is labeled "idiopathic" when no clear secondary cause is identified, though it can be triggered by various underlying factors such as autoimmune diseases or infections. IMN generally affects adults, especially middle-aged men, and presents with symptoms like frothy urine, swelling in the legs and abdomen, and weight gain due to fluid buildup. Diagnosing IMN involves both clinical evaluation and laboratory tests. Initial tests include urine analysis to detect high levels of protein (usually over 3.5 g/day), which is characteristic of nephrotic syndrome. Blood tests are used to assess kidney function and identify hypoalbuminemia and dyslipidemia, both common in nephrotic syndrome. A kidney biopsy is often needed to confirm the diagnosis, revealing typical changes in the glomeruli, such as immune complex deposits along the capillary walls. Additionally, serological tests for specific antibodies, like those targeting the phospholipase A2 receptor (PLA2R), can help distinguish primary IMN from secondary forms, aiding in the development of appropriate treatment plans. Idiopathic Membranous Nephropathy Epidemiology Segmentation DelveInsight's Idiopathic Membranous Nephropathy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Idiopathic Membranous Nephropathy historical patient pools and forecasted Idiopathic Membranous Nephropathy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Idiopathic Membranous Nephropathy Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into: Idiopathic Membranous Nephropathy Prevalence Age-Specific Idiopathic Membranous Nephropathy Prevalence Gender-Specific Idiopathic Membranous Nephropathy Prevalence Diagnosed and Treatable Cases of Idiopathic Membranous Nephropathy Idiopathic Membranous Nephropathy Market Outlook The Idiopathic Membranous Nephropathy (IMN) market is driven by several key factors, including the rising prevalence of chronic kidney diseases globally, improved diagnostic capabilities enabling early detection, and increased awareness among physicians and patients. The development of novel biomarkers and targeted biologics, along with the growing adoption of personalized medicine approaches, are also fueling market growth. Additionally, supportive reimbursement policies and ongoing clinical trials exploring innovative therapies contribute to market expansion. However, significant barriers persist, such as the high cost of advanced treatments and limited accessibility in low- and middle-income regions. The heterogeneity of disease progression complicates clinical management, often delaying optimal intervention. Moreover, stringent regulatory requirements and lengthy approval timelines for new therapeutics pose challenges for manufacturers. A lack of comprehensive long-term safety data on emerging therapies and concerns regarding potential adverse effects further restrict widespread adoption. Together, these drivers and barriers shape the evolving landscape of the IMN market, highlighting both opportunities for advancement and areas requiring strategic focus to address unmet needs. Major companies like Hoffmann-La Roche, HI-Bio, Cerium Pharmaceuticals, BeiGene, and others are advancing their lead candidates through various stages of clinical development, with the goal of exploring their products for the treatment of Idiopathic Membranous Nephropathy. Idiopathic Membranous Nephropathy Emerging Drugs Idiopathic Membranous Nephropathy Key Companies Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astellas Pharma Inc., Baxter Healthcare Corporation, Sigma Aldrich Corporation, and others Scope of the Idiopathic Membranous Nephropathy Market Report: 10 Years Forecast 7MM Coverage Descriptive overview of Idiopathic Membranous Nephropathy, causes, signs and symptoms, diagnosis, treatment Comprehensive insight into Idiopathic Membranous Nephropathy epidemiology in the 7MM Idiopathic Membranous Nephropathy marketed and emerging therapies Idiopathic Membranous Nephropathy companies Idiopathic Membranous Nephropathy market drivers and barriers Table of Contents: 1 Idiopathic Membranous Nephropathy Market Key Comprehensive Insights 2 Idiopathic Membranous Nephropathy Market Report Introduction 3 Competitive Intelligence Analysis for Idiopathic Membranous Nephropathy 4 Idiopathic Membranous Nephropathy Market Analysis Overview at a Glance 5 Executive Summary of Idiopathic Membranous Nephropathy 6 Idiopathic Membranous Nephropathy Epidemiology and Market Methodology 7 Idiopathic Membranous Nephropathy Epidemiology and Patient Population 8 Idiopathic Membranous Nephropathy Patient Journey 9 Idiopathic Membranous Nephropathy Treatment Algorithm, Idiopathic Membranous Nephropathy Current Treatment, and Medical Practices 10 Key Endpoints in Idiopathic Membranous Nephropathy Clinical Trials 11 Idiopathic Membranous Nephropathy Marketed Therapies 12 Idiopathic Membranous Nephropathy Emerging Therapies 13 Idiopathic Membranous Nephropathy: 7 Major Market Analysis 14 Attribute analysis 15 Access and Reimbursement Overview of Idiopathic Membranous Nephropathy 16 Idiopathic Membranous Nephropathy Market Key Opinion Leaders Reviews 18 Idiopathic Membranous Nephropathy Market Drivers 19 Idiopathic Membranous Nephropathy Market Barriers 20 SWOT Analysis 21 Disclaimer 22 DelveInsight Capabilities 23 About DelveInsight About DelveInsight DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Globe and Mail
30-06-2025
- Business
- Globe and Mail
Complicated Urinary Tract Infection (cUTI) Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Prevalence, Statistics, Revenue, Therapies, Companies by DelveInsight
Complicated Urinary Tract Infection (cUTI) companies are Pfizer, Novartis, Spero Therapeutics, Tetraphase Pharmaceuticals, Wockhardt, Venatorx Pharmaceuticals, Cubist Pharmaceuticals, Janssen, Allecra Therapeutics, Nabriva Therapeutics AG, La Jolla Pharmaceutical Company, MerLion Pharmaceuticals, PRA Health Sciences, Qilu Pharmaceutical, Meiji Seika Pharma and others. (Albany, USA) DelveInsight's " Complicated Urinary Tract Infection (cUTI) Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Complicated Urinary Tract Infection (cUTI), historical and forecasted epidemiology as well as the Complicated Urinary Tract Infection (cUTI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Complicated Urinary Tract Infection (cUTI) market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Complicated Urinary Tract Infection (cUTI) market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Complicated Urinary Tract Infection (cUTI) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Complicated Urinary Tract Infection (cUTI) market. Some facts of the Complicated Urinary Tract Infection (cUTI) Market Report are: According to DelveInsight, Complicated Urinary Tract Infection (cUTI) market size is expected to grow at a decent CAGR by 2034. In June 2025, Menarini Group announced a clinical trial is to assess the pharmacokinetic (PK) and safety and tolerability of Vaborem ( fixed combination of meropenem and vaborbactam) in the paediatric population aged from 3 months to < 18 years with complicated urinary tract infection (cUTI) including acute pyelonephritis (AP) in need of hospitalisation and intravenous (IV) antibiotic administration. In June 2025, Venatorx Pharmaceuticals Inc. conducted a Phase 3 study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis. In June 2025, Rempex organized a study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). In April 2025, Rempex announced a study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). In April 2025, Menarini Group announced clinical trial is to assess the pharmacokinetic (PK) and safety and tolerability of Vaborem ( fixed combination of meropenem and vaborbactam) in the paediatric population aged from 3 months to < 18 years with complicated urinary tract infection (cUTI) including acute pyelonephritis (AP) in need of hospitalisation and intravenous (IV) antibiotic administration. In April 2025, Shionogi announced a study is to understand the pharmacokinetics (PK) of single and multiple doses of cefiderocol in children from birth to less than 3 months of age with suspected or confirmed aerobic Gram-negative bacterial infections. In the 7MM, nearly 1,000,000 cUTI incident cases progressed from uUTI in the year 2023, which is expected to increase during the forecast period (2024-2034). In the US, maximum number of cUTI cases were observed for the age group of 65-84 years, followed by =85 years. Among the EU4 and the UK, Germany recorded the highest number of diagnosed-incident cases of cUTI with approximately 26% cases in 2023, which is estimated to rise by 2034, at a CAGR of 0.6%. Japan accounted for around 800,000 cases of cUTI in 2023 caused due to Uropathogenic Escherichia coli, followed by 100,000 cases caused by Klebsiella pneumonia. Leading Complicated Urinary Tract Infection (cUTI) companies working in the market are Pfizer, Novartis, Spero Therapeutics, Tetraphase Pharmaceuticals, Wockhardt, Venatorx Pharmaceuticals, Cubist Pharmaceuticals, Janssen, Allecra Therapeutics, Nabriva Therapeutics AG, La Jolla Pharmaceutical Company, MerLion Pharmaceuticals, PRA Health Sciences, Qilu Pharmaceutical, Meiji Seika Pharma and others. Key Complicated Urinary Tract Infection (cUTI) Therapies expected to launch in the market are Ceftazidime –avibactam, Cefepime, LYS228, Eravacycline, Ertapenem, Levofloxacin, CXA-101, TBPM-PI-HBr, Doripenem, Meropenem- FL058, Piperacillin –tazobactam, aztreonam and nacubactam, cefepime and nacubactam, Sulopenem Etzadroxil/Probenecid, Meropenem, Cefepime-zidebactam (FEP-ZID), and others. On June 2023, Meiji Seika Pharma Co announced a Phase 3 study to evaluate the efficacy and safety of cefepime/nacubactam or aztreonam/nacubactam compared to imipenem/cilastatin in the treatment of complicated urinary tract infections (cUTI) or acute uncomplicated pyelonephritis (AP). On May 2023, Wockhardt announced a Phase 3, randomized, double-blind, multicenter, non-inferiority study to evaluate the efficacy, safety, and tolerability of FEP-ZID vs. meropenem in the treatment of hospitalized adults with Complicated Urinary Tract Infection or AP. Complicated Urinary Tract Infection (cUTI) Overview A complicated urinary tract infection (UTI) refers to an infection that occurs in the urinary tract and is associated with additional factors or conditions that make it more challenging to diagnose, treat, or resolve. These factors can include urinary tract abnormalities, obstruction, kidney stones, immunocompromised state, diabetes, pregnancy, catheterization, or antibiotic resistance. Complicated UTIs may involve not only the lower urinary tract (bladder and urethra) but also the upper urinary tract (kidneys and ureters). The complexity of these infections often necessitates a multidimensional approach, including targeted antibiotic therapy, identification and management of underlying factors, and close monitoring for potential complications. Complicated Urinary Tract Infection (cUTI) Market The Complicated Urinary Tract Infection (cUTI) market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Complicated Urinary Tract Infection (cUTI) market trends by analyzing the impact of current Complicated Urinary Tract Infection (cUTI) therapies on the market and unmet needs, and drivers, barriers, and demand for better technology. This segment gives a thorough detail of the Complicated Urinary Tract Infection (cUTI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Complicated Urinary Tract Infection (cUTI) market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Complicated Urinary Tract Infection (cUTI) market in 7MM is expected to witness a major change in the study period 2020-2034. Complicated Urinary Tract Infection (cUTI) Epidemiology The Complicated Urinary Tract Infection (cUTI) epidemiology section provides insights into the historical and current Complicated Urinary Tract Infection (cUTI) patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Complicated Urinary Tract Infection (cUTI) market report also provides the diagnosed patient pool, trends, and assumptions. Complicated Urinary Tract Infection (cUTI) Drugs Uptake This section focuses on the uptake rate of the potential Complicated Urinary Tract Infection (cUTI) drugs recently launched in the Complicated Urinary Tract Infection (cUTI) market or expected to be launched in 2020-2034. The analysis covers the Complicated Urinary Tract Infection (cUTI) market uptake by drugs, patient uptake by therapies, and sales of each drug. Complicated Urinary Tract Infection (cUTI) Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Complicated Urinary Tract Infection (cUTI) market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Complicated Urinary Tract Infection (cUTI) Pipeline Development Activities The Complicated Urinary Tract Infection (cUTI) report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Complicated Urinary Tract Infection (cUTI) key players involved in developing targeted therapeutics. Complicated Urinary Tract Infection (cUTI) Therapeutics Assessment Major key companies are working proactively in the Complicated Urinary Tract Infection (cUTI) Therapeutics market to develop novel therapies which will drive the Complicated Urinary Tract Infection (cUTI) treatment markets in the upcoming years are Pfizer, Novartis, Spero Therapeutics, Tetraphase Pharmaceuticals, Wockhardt, Venatorx Pharmaceuticals, Cubist Pharmaceuticals, Janssen, Allecra Therapeutics, Nabriva Therapeutics AG, La Jolla Pharmaceutical Company, MerLion Pharmaceuticals, PRA Health Sciences, Qilu Pharmaceutical, Meiji Seika Pharma and others. Complicated Urinary Tract Infection (cUTI) Report Key Insights 1. Complicated Urinary Tract Infection (cUTI) Patient Population 2. Complicated Urinary Tract Infection (cUTI) Market Size and Trends 3. Key Cross Competition in the Complicated Urinary Tract Infection (cUTI) Market 4. Complicated Urinary Tract Infection (cUTI) Market Dynamics (Key Drivers and Barriers) 5. Complicated Urinary Tract Infection (cUTI) Market Opportunities 6. Complicated Urinary Tract Infection (cUTI) Therapeutic Approaches 7. Complicated Urinary Tract Infection (cUTI) Pipeline Analysis 8. Complicated Urinary Tract Infection (cUTI) Current Treatment Practices/Algorithm 9. Impact of Emerging Therapies on the Complicated Urinary Tract Infection (cUTI) Market Table of Contents 1. Key Insights 2. Executive Summary 3. Complicated Urinary Tract Infection (cUTI) Competitive Intelligence Analysis 4. Complicated Urinary Tract Infection (cUTI) Market Overview at a Glance 5. Complicated Urinary Tract Infection (cUTI) Disease Background and Overview 6. Complicated Urinary Tract Infection (cUTI) Patient Journey 7. Complicated Urinary Tract Infection (cUTI) Epidemiology and Patient Population 8. Complicated Urinary Tract Infection (cUTI) Treatment Algorithm, Current Treatment, and Medical Practices 9. Complicated Urinary Tract Infection (cUTI) Unmet Needs 10. Key Endpoints of Complicated Urinary Tract Infection (cUTI) Treatment 11. Complicated Urinary Tract Infection (cUTI) Marketed Products 12. Complicated Urinary Tract Infection (cUTI) Emerging Therapies 13. Complicated Urinary Tract Infection (cUTI) Seven Major Market Analysis 14. Attribute Analysis 15. Complicated Urinary Tract Infection (cUTI) Market Outlook (7 major markets) 16. Complicated Urinary Tract Infection (cUTI) Access and Reimbursement Overview 17. KOL Views on the Complicated Urinary Tract Infection (cUTI) Market 18. Complicated Urinary Tract Infection (cUTI) Market Drivers 19. Complicated Urinary Tract Infection (cUTI) Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer About DelveInsight DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Globe and Mail
23-06-2025
- Health
- Globe and Mail
Alopecia Areata Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Therapies, Epidemiology, Revenue, Statistics, Medication, and Companies by DelveInsight
"Alopecia Areata Drugs Market" Alopecia Areata companies are Arcutis Biotherapeutics, Bioniz Therapeutics, Reistone Biopharma Company, Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly, Incyte Corporation, Aclaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, LEO Pharma, Bristol-Myers Squibb, and others. (Albany, USA) DelveInsight's " Alopecia Areata Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The market report on Alopecia Areata presents up-to-date information on treatment approaches, emerging medications, the market share of different therapies, and the current as well as projected Alopecia Areata market size from 2020 to 2034, across seven major markets. The report includes details on the prevailing treatment practices and guidelines for Alopecia Areata, along with an analysis of market drivers, barriers, and unmet medical needs. This comprehensive assessment aims to identify the most promising opportunities and evaluate the overall potential of the Alopecia Areata market. Some facts of the Alopecia Areata Market Report are: According to DelveInsight, Alopecia Areata Market is expected to grow at a CAGR of ~27% by 2034. According to DelveInsight's patient-based forecasting model, the total market size of Alopecia Areata in the 7MM was around USD 180 million in 2023. Leading Alopecia Areata companies working in the market are Arcutis Biotherapeutics, Bioniz Therapeutics, Reistone Biopharma Company, Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly, Incyte Corporation, Aclaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, LEO Pharma, Bristol-Myers Squibb, And Many Others Key Alopecia Areata Therapies expected to launch in the market are Abatacept, Tralokinumab, Secukinumab, BNZ 1, Ritlecitinib, Ifidancitinib, Coacillium topical, Delgocitinib, Etrasimod, Brepocitinib, ATI 1777, Baricitinib, and several others. The increasing R&D investments for strong Alopecia Areata pipeline candidates by prominent players such as Arcutis Biotherapeutics, Bioniz Therapeutics, Pfizer, Eli Lilly and Company, Reistone Biopharma Company, Concert Pharmaceuticals, and others will contribute positively to the Alopecia Areata treatment landscape in the forthcoming years. Alopecia Areata Overview Alopecia areata is an autoimmune disorder that results in sudden hair loss. It occurs when the immune system mistakenly targets hair follicles, causing them to shrink and enter a dormant phase. This leads to hair thinning or complete hair loss in round or oval patches on the scalp or other parts of the body. The exact cause of alopecia areata is not fully understood, but it is believed to involve a combination of genetic and environmental factors. It can affect individuals of any age, gender, or ethnic background. While alopecia areata is generally not a life-threatening condition, it can have a significant psychological and emotional impact on those affected. The unpredictable nature of hair loss and its potential for recurrence can cause distress and self-esteem issues. There is currently no known cure for alopecia areata, but various treatment options aim to stimulate hair regrowth and manage the condition. These may include topical corticosteroids, topical immunotherapy, oral medications, and injectable medications. Hairpieces, wigs, or cosmetic camouflage techniques can also be utilized to cover areas of hair loss. Learn more about Alopecia Areata treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Alopecia Areata Treatment Market Alopecia Areata Market The Alopecia Areata market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Alopecia Areata market trends by analyzing the impact of current Alopecia Areata therapies on the market and unmet needs, and drivers, barriers, and demand for better technology. This segment gives a thorough detail of the Alopecia Areata market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Alopecia Areata market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Alopecia Areata market in 7MM is expected to witness a major change in the study period 2020-2034. Alopecia Areata Epidemiology The Alopecia Areata epidemiology section provides insights into the historical and current Alopecia Areata patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Alopecia Areata market report also provides the diagnosed patient pool, trends, and assumptions. Alopecia Areata Drugs Uptake This section focuses on the uptake rate of the potential Alopecia Areata drugs recently launched in the Alopecia Areata market or expected to be launched in 2020-2034. The analysis covers the Alopecia Areata market uptake by drugs, patient uptake by therapies, and sales of each drug. Alopecia Areata Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Alopecia Areata market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Alopecia Areata Pipeline Development Activities The Alopecia Areata report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses key Alopecia Areata companies involved in developing targeted therapeutics. Alopecia Areata Therapeutics Assessment Major key companies are working proactively in the Alopecia Areata Therapeutics market to develop novel therapies which will drive the Alopecia Areata treatment markets in the upcoming years are Arcutis Biotherapeutics, Bioniz Therapeutics, Reistone Biopharma Company, Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly, Incyte Corporation, Aclaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, LEO Pharma, Bristol-Myers Squibb, And Many Others. Scope of the Alopecia Areata Market Report: Coverage: 7MM Study Period: 2020-2034 Alopecia Areata Companies: Arcutis Biotherapeutics, Bioniz Therapeutics, Pfizer, Eli Lilly and Company, Reistone Biopharma Company, Concert Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, Legacy Healthcare, Arena Pharmaceuticals, LEO Pharma, Aclaris Therapeutics, Bristol-Myers Squibb, Novartis, and many others. Alopecia Areata Drugs: Abatacept, Tralokinumab, Secukinumab, BNZ 1, Ritlecitinib, Ifidancitinib, Coacillium topical, Delgocitinib, Etrasimod, Brepocitinib, ATI 1777, Baricitinib, and several others. Alopecia Areata Report Key Insights 1. Alopecia Areata Patient Population 2. Alopecia Areata Market Size and Trends 3. Key Cross Competition in the Alopecia Areata Market 4. Alopecia Areata Market Dynamics (Key Drivers and Barriers) 5. Alopecia Areata Market Opportunities 6. Alopecia Areata Therapeutic Approaches 7. Alopecia Areata Pipeline Analysis 8. Alopecia Areata Current Treatment Practices/Algorithm 9. Impact of Emerging Therapies on the Alopecia Areata Market Table of Contents 1. Key Insights 2. Executive Summary 3. Alopecia Areata Competitive Intelligence Analysis 4. Alopecia Areata Market Overview at a Glance 5. Alopecia Areata Disease Background and Overview 6. Alopecia Areata Patient Journey 7. Alopecia Areata Epidemiology and Patient Population 8. Alopecia Areata Treatment Algorithm, Current Treatment, and Medical Practices 9. Alopecia Areata Unmet Needs 10. Key Endpoints of Alopecia Areata Treatment 11. Alopecia Areata Marketed Products 12. Alopecia Areata Emerging Therapies 13. Alopecia Areata Seven Major Market Analysis 14. Attribute Analysis 15. Alopecia Areata Market Outlook (7 major markets) 16. Alopecia Areata Access and Reimbursement Overview 17. KOL Views on the Alopecia Areata Market 18. Alopecia Areata Market Drivers 19. Alopecia Areata Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer About DelveInsight DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Globe and Mail
16-06-2025
- Business
- Globe and Mail
PD-L1 Inhibitors Market Insight, Epidemiology, and Market Forecast – 2034
PD-L1 inhibitors have become a vital part of modern cancer therapy by blocking the PD-1/PD-L1 pathway, which tumors use to evade immune detection. By restoring T-cell function, these therapies boost the body's ability to fight cancer. They have shown significant clinical benefit, including durable responses and improved survival, in several cancers such as NSCLC, TNBC, renal cell carcinoma, urothelial carcinoma, and head and neck squamous cell carcinoma. DelveInsight's ' PD-L1 Inhibitors Market Report ' provides an in-depth analysis of the current and future market landscape for PD-L1 inhibitors across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and other key geographies. The report offers comprehensive epidemiological insights, treatment algorithms, evolving biomarker trends, and the competitive environment surrounding PD-L1-targeting therapies. Currently marketed PD-L1 inhibitors, including TECENTRIQ, IMFINZI, and BAVENCIO, have expanded their indications through successful regulatory approvals. These agents are widely used as monotherapy or in combination with chemotherapy, anti-VEGF agents, or other immune checkpoint inhibitors, depending on cancer type and biomarker expression. The market is witnessing dynamic growth driven by increasing PD-L1 biomarker testing, expanded indications, strategic collaborations, and next-generation immuno-oncology research. The development pipeline includes novel PD-L1 inhibitors, bispecific antibodies, and combination regimens aimed at overcoming resistance and improving patient outcomes. Companies such as EQRx, CStone Pharmaceuticals, Pfizer, Novartis, and others are leading the field with continuous investment in clinical trials and label expansions. However, challenges persist, including the identification of optimal biomarkers for patient selection, immune-related adverse events, resistance mechanisms, and cost-effectiveness concerns. Despite these hurdles, the PD-L1 inhibitor market is expected to grow substantially through 2034, supported by ongoing innovations, broader clinical acceptance, and rising global cancer burden. This report serves as a vital resource for pharmaceutical companies, investors, clinical researchers, and oncologists looking to navigate the evolving PD-L1 inhibitor landscape, assess market opportunities, and drive strategic decision-making. Some of the Key Facts of the PD-L1 Inhibitors Market Report: • In 2023, the PD-L1 inhibitors market size in the 7MM was approximately USD 36 billion, with the United States contributing the largest share. • Key indications in the U.S. (2023 incident cases): • KEYTRUDA and OPDIVO, the leading PD-L1 inhibitors, are expected to lose patent exclusivity in the U.S. by 2028, potentially impacting market dynamics. • The loss of exclusivity may lead to a market decline, as biosimilars emerge and new entrants may struggle to match the current dominance of KEYTRUDA and OPDIVO, even with approvals in multiple indications. • Clinical trial activity has surged, over 4,400 trials registered, with more than 3,600 ongoing. • Around 90% of new trials since 2020 are exploring PD-L1 inhibitors in combination regimens, highlighting a strong shift towards combination strategies. • In April 2025, Gilead Sciences reported positive results from the Phase III ASCENT-04/KEYNOTE-D19 study, showing that the combination of TRODELVY (sacituzumab govitecan-hziy) and KEYTRUDA (pembrolizumab) significantly improved progression-free survival in patients with metastatic triple-negative breast cancer (mTNBC) whose tumors express PD-L1 (CPS ≥ 10), compared to chemotherapy and KEYTRUDA alone. • In March 2025, the FDA granted traditional approval for frontline pembrolizumab (Keytruda) in combination with trastuzumab and chemotherapy (fluoropyrimidine- and platinum-based) for adults with locally advanced, unresectable, or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) of at least 1 (CPS ≥1). • In March 2025, the FDA granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-based chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1). • In February 2025, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) status to nogapendekin alfa (Anktiva) and CAR-NK (PD-L1 t-haNK) for their potential to reverse lymphopenia in patients undergoing chemotherapy/radiotherapy and to treat metastatic pancreatic cancer. • In February 2025, Beijing Biostar Pharmaceuticals announced that its Utidelone Capsules, in combination with capecitabine and oxaliplatin, received FDA approval for a Phase II/III registration clinical study (BG02-2404). This Combination Therapy is for first-line treatment of PD-L1-negative, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. • In January 2025, the FDA approved tislelizumab, in combination with platinum- and fluoropyrimidine-based chemotherapy, for the first-line treatment of patients with unresectable or metastatic, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (≥1). • Leading companies in the PD-L1 Inhibitors market include EQRx, CStone Pharmaceuticals, Pfizer, Novartis, Arcus Biosciences, Agenus, TRACON Pharmaceuticals, Shanghai Henlius Biotech, Incyte Corporation, and others. • Emerging acute PD-L1 inhibitor drugs include Sugemalimab (CS1001), Sasanlimab, Spartalizumab, Zimberelimab, Balstilimab, Envafolimab, HLX10, INCB099280, and others. • PD-L1 inhibitors are reshaping cancer care, fueling demand for more targeted and durable treatment options across multiple tumor types with growing clinical adoption and expanding indications. To know in detail about the PD-L1 Inhibitors market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: PD-L1 Inhibitors Overview Programmed death-ligand 1 (PD-L1) inhibitors are a class of immune checkpoint inhibitors that have revolutionized cancer immunotherapy by enhancing the body's natural ability to fight tumors. PD-L1 is a protein expressed on tumor cells and tumor-infiltrating immune cells that binds to the PD-1 receptor on T-cells, effectively turning off the immune response. By blocking this interaction, PD-L1 inhibitors restore T-cell activity, allowing the immune system to recognize and destroy cancer cells more effectively. PD-L1 inhibitors are currently approved for a variety of malignancies, including non-small cell lung cancer (NSCLC), urothelial carcinoma, triple-negative breast cancer (TNBC), hepatocellular carcinoma, and others. Some of the key PD-L1 inhibitors include atezolizumab (TECENTRIQ), durvalumab (IMFINZI), and avelumab (BAVENCIO). These therapies are often used either as monotherapy or in combination with chemotherapy, targeted therapy, or other immunotherapies. Ongoing research continues to expand its applications across tumor types and disease stages, and the development of predictive biomarkers aims to refine patient selection for optimal treatment outcomes. With multiple agents in clinical and preclinical development, PD-L1 inhibitors remain a cornerstone of immuno-oncology, offering the potential for improved survival, long-term remission, and better quality of life for patients with advanced cancers. Get a free sample of the PD-L1 Inhibitors market report with key insights and emerging therapies here: PD-L1 Inhibitors Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Download the report to understand which factors are driving PD-L1 Inhibitors epidemiology trends @ PD-L1 Inhibitors Epidemiology Forecast PD-L1 Inhibitor Drugs Uptake and Pipeline Development Activities The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the PD-L1 Inhibitors market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug. Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share. The report further delves into the PD-L1 Inhibitors pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies. PD-L1 Inhibitors Market Outlook The PD-L1 inhibitors market is poised for continued growth, with PD-1/PD-L1 inhibitors expected to lead oncology drug sales in the coming years. These immuno-oncology agents have revolutionized cancer care across various tumor types and stages, from metastatic to early disease, thanks to their adaptability and durable clinical benefits. Widely adopted as monotherapy or in combination with tyrosine kinase inhibitors, chemotherapy, or other immunotherapies, PD-L1 inhibitors offer prolonged tumor responses and enhanced survival outcomes while maintaining a favorable safety profile that supports their use in broad combination regimens. While immune checkpoint inhibitors have transformed the cancer treatment landscape, efforts to target pathways beyond PD-1/PD-L1—such as TIGIT, TIM-3, and LAG-3—have met with limited success, though some agents continue development. Innovative approaches like Eftilagimod alpha (Efti), a unique MHC Class II agonist, are also gaining attention for combination strategies. In an increasingly crowded PD-L1 market, innovation and differentiation are critical. Companies must target new indications, address current treatment gaps, or become first-in-class to maintain a competitive advantage. Emerging PD-L1 inhibitors such as spartalizumab (Novartis), sasanlimab (Pfizer), zimberelimab (Arcus Biosciences), sugemalimab (EQRx/CStone), HLX10 (Henlius), and balstilimab (Agenus) are currently in development. Among the 7MM, the United States remains the largest market for PD-L1 inhibitors, generating nearly USD 26 billion in 2023, with further expansion anticipated through 2034. PD-L1 Inhibitors Market Strengths • PD-L1 inhibitors are approved for a wide range of tumor types, including non-small cell lung cancer, bladder cancer, melanoma, and more. Their use as monotherapy or in combination regimens gives them a significant advantage in oncology treatment strategies. • With numerous promising candidates in clinical development, such as spartalizumab, sasanlimab, and sugemalimab, the pipeline remains robust. Continued R&D investment ensures ongoing evolution and expansion into new indications and combinations. PD-L1 Inhibitors Market Weaknesses • The PD-L1 inhibitors landscape is crowded with multiple approved agents and late-stage candidates, making it difficult for new entrants to differentiate and capture market share without clear clinical or safety advantages. • Attempts to extend the checkpoint blockade approach beyond PD-1/PD-L1 (e.g., targeting TIGIT, TIM-3) have faced clinical setbacks. This limits expansion opportunities and raises concerns about over-reliance on the PD-1/PD-L1 axis. Scope of the PD-L1 Inhibitors Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] • Key PD-L1 Inhibitors Companies: EQRx, CStone Pharmaceuticals, Pfizer, Novartis, Arcus Biosciences, Agenus, TRACON Pharmaceuticals, Shanghai Henlius Biotech, Incyte Corporation, and others. • Key PD-L1 Inhibitors Therapies: Sugemalimab (CS1001), Sasanlimab, Spartalizumab, Zimberelimab, Balstilimab, Envafolimab, HLX10, INCB099280, and others. • PD-L1 Inhibitors Therapeutic Assessment: PD-L1 Inhibitors, currently marketed, and PD-L1 Inhibitors emerging therapies • PD-L1 Inhibitors Market Dynamics: PD-L1 Inhibitors market drivers and PD-L1 Inhibitors market barriers • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies • PD-L1 Inhibitors Unmet Needs, KOL's views, Analyst's views, PD-L1 Inhibitors Market Access and Reimbursement Table of Contents 1. PD-L1 Inhibitors Market Report Introduction 2. Executive Summary for PD-L1 Inhibitors 3. SWOT analysis of PD-L1 Inhibitors 4. PD-L1 Inhibitors Patient Share (%) Overview at a Glance 5. PD-L1 Inhibitors Market Overview at a Glance 6. PD-L1 Inhibitors Disease Background and Overview 7. PD-L1 Inhibitors Epidemiology and Patient Population 8. Country-Specific Patient Population of PD-L1 Inhibitors 9. PD-L1 Inhibitors Current Treatment and Medical Practices 10. PD-L1 Inhibitors Unmet Needs 11. PD-L1 Inhibitors Emerging Therapies 12. PD-L1 Inhibitors Market Outlook 13. Country-Wise PD-L1 Inhibitors Market Analysis (2020–2034) 14. PD-L1 Inhibitors Market Access and Reimbursement of Therapies 15. PD-L1 Inhibitors Market Drivers 16. PD-L1 Inhibitors Market Barriers 17. PD-L1 Inhibitors Appendix 18. PD-L1 Inhibitors Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Globe and Mail
16-06-2025
- Health
- Globe and Mail
Opioid Withdrawal Syndrome Market Insight, Epidemiology, and Market Forecast – 2034
Opioid Withdrawal Syndrome (OWS) is a major public health concern caused by the sudden reduction or cessation of opioids in dependent individuals. Symptoms like anxiety, cramps, and severe cravings make withdrawal a key barrier to recovery. With the ongoing opioid crisis, the demand for effective, accessible treatments continues to grow. DelveInsight's ' Opioid Withdrawal Syndrome Market Report ' offers a detailed analysis of the current and projected landscape for OWS treatment across the major markets, including the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report outlines the evolving epidemiology, highlighting the high prevalence of opioid dependence and withdrawal cases, particularly in countries severely impacted by opioid misuse. It also examines standard clinical practices and treatment gaps, providing a strategic overview of the healthcare burden and future market potential. Current treatment regimens for OWS typically involve a combination of opioid agonists such as buprenorphine and methadone, non-opioid medications like clonidine and lofexidine, and supportive symptom-based therapies. While effective to some extent, these approaches often face challenges related to tolerability, relapse risk, and access to care. The approval of non-opioid therapies like Lucemyra (lofexidine hydrochloride) has expanded options for managing withdrawal symptoms, but broader therapeutic innovation remains limited. Newer candidates in clinical development are targeting novel pathways to reduce withdrawal intensity and improve adherence during detoxification. With rising investments in addiction research, increasing awareness around opioid misuse, and supportive policy reforms in many countries, the OWS treatment market is set to evolve significantly by 2034. DelveInsight's report captures this transformation by evaluating market dynamics, key players, emerging therapies, and regulatory landscapes. It is an essential resource for pharmaceutical companies, healthcare providers, policymakers, and investors looking to understand and capitalize on the opportunities in this high-need therapeutic area. Some of the Key Facts of the Opioid Withdrawal Syndrome Market Report: • In 2022, the Opioid Withdrawal Syndrome market in the 7MM was valued at around USD 1.3 billion and is expected to grow steadily through 2034. • Approximately 8.2 million cases of opioid withdrawal syndrome were reported in the 7MM in 2022, with a projected decline over the forecast period. • Around 9.1 million individuals had long-term opioid use in the 7MM in 2022. • The US accounted for nearly 7.1 million opioid withdrawal cases in 2022, expected to decrease by 2034. • In March 2025, Hikma Pharmaceuticals announced that Health Canada approved KLOXXADO® (naloxone HCl) Nasal Spray 8 mg for the treatment of known or suspected opioid overdose, characterized by respiratory and/or central nervous system depression, in adult patients. • In February 2025, Indivior announced that the FDA approved label changes for SUBLOCADE® injection, a treatment for moderate to severe opioid use disorder (OUD). The updates include a rapid initiation protocol reducing treatment time from one week to one hour and alternative injection sites to improve flexibility and patient adherence. • In October 2024, the FDA approved Protega Pharmaceuticals' ROXYBOND™ (oxycodone IR 10 mg) for severe pain management. It is the first FDA-approved abuse-deterrent IR oxycodone designed to reduce intranasal and intravenous misuse. • Leading companies in the Opioid Withdrawal Syndrome market include atai Life Sciences, Medicinova, BioXcel Therapeutics Inc., and others. • Emerging acute Opioid Withdrawal Syndrome drugs include BXCL501, MN-166, DMX-1002, and others. • Opioid Withdrawal Syndrome remains a significant clinical challenge, with rising awareness and evolving treatment strategies driving demand for safer, more effective therapies to manage symptoms and reduce relapse risk. To know in detail about the Opioid Withdrawal Syndrome market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Opioid Withdrawal Syndrome Market Forecast Opioid Withdrawal Syndrome Overview Opioid Withdrawal Syndrome (OWS) is a clinical condition that occurs when individuals who are physically dependent on opioids suddenly reduce or discontinue their use. This syndrome is a hallmark of opioid dependence and is driven by the neuroadaptive changes in the brain that result from prolonged exposure to opioids. When opioid use is stopped, the abrupt absence of the drug leads to a rebound of neurotransmitter activity, particularly within the noradrenergic and dopaminergic systems, triggering a range of distressing physical and psychological symptoms. Symptoms of opioid withdrawal typically begin within hours of the last dose and can vary in intensity depending on the type of opioid used, duration of use, and individual factors such as tolerance and overall health. Common early symptoms include anxiety, agitation, muscle aches, sweating, and insomnia. These may progress to more severe manifestations such as abdominal cramps, vomiting, diarrhea, dilated pupils, rapid heartbeat, and intense cravings. While not usually life-threatening, the severity of symptoms can lead to significant discomfort and increase the risk of relapse. Get a free sample of the Opioid Withdrawal Syndrome market report with key insights and emerging therapies here: Opioid Withdrawal Syndrome Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Opioid Withdrawal Syndrome Epidemiology Segmentation: The Opioid Withdrawal Syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by: • Number of Opioid Misuse Cases • Number of Cases with long term Opioid usage • Total Opioid Withdrawal symptoms Cases Download the report to understand which factors are driving Opioid Withdrawal Syndrome epidemiology trends @ Opioid Withdrawal Syndrome Epidemiology Forecast Opioid Withdrawal Syndrome Drugs Uptake and Pipeline Development Activities The Opioid Withdrawal Syndrome drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the Opioid Withdrawal Syndrome market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug. Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share. The report further delves into the Opioid Withdrawal Syndrome pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies. Opioid Withdrawal Syndrome Market Outlook The Opioid Withdrawal Syndrome (OWS) market is expected to witness steady growth through 2034, driven by the increasing prevalence of opioid use disorder (OUD), rising awareness about withdrawal management, and expanding access to treatment services. As the opioid crisis continues to pose a significant public health burden across the globe, particularly in the United States and parts of Europe, the demand for effective withdrawal therapies is accelerating. The availability of both opioid-based and non-opioid pharmacological options, including buprenorphine and clonidine, is enhancing treatment outcomes and reducing relapse rates, contributing to market expansion. Furthermore, advancements in withdrawal management protocols, growing governmental and private sector investments in addiction care, and the development of more targeted and patient-friendly therapeutics are fueling innovation in the OWS treatment landscape. The emergence of new formulations, such as long-acting buprenorphine and novel non-opioid agents, is expected to diversify the treatment arsenal and improve patient adherence. With continued efforts toward destigmatization and the integration of mental health support, the OWS market is poised for sustained progress over the forecast period. Opioid Withdrawal Syndrome Market Strengths • Increased global awareness about the opioid crisis, coupled with supportive government policies, funding, and public health initiatives, has significantly strengthened the market. Programs promoting medication-assisted treatment (MAT) and opioid withdrawal management have expanded access to care, thereby boosting demand for therapeutic options. • The development of innovative pharmacological treatments, such as non-opioid medications (e.g., lofexidine) and extended-release formulations of buprenorphine, has improved treatment adherence and outcomes. These advancements enhance patient experience and create opportunities for differentiated products in the market. Opioid Withdrawal Syndrome Market Weaknesses • Despite increasing awareness, societal stigma associated with opioid dependence continues to prevent many individuals from seeking help. Underreporting and underdiagnosis of OWS limit the true market potential and delay access to treatment. • Despite increasing awareness, societal stigma associated with opioid dependence continues to prevent many individuals from seeking help. Underreporting and underdiagnosis of OWS limit the true market potential and delay access to treatment. Scope of the Opioid Withdrawal Syndrome Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] • Key Opioid Withdrawal Syndrome Companies: atai Life Sciences, Medicinova, BioXcel Therapeutics Inc., and others. • Key Opioid Withdrawal Syndrome Therapies: BXCL501, MN-166, DMX-1002, and others. • Opioid Withdrawal Syndrome Therapeutic Assessment: Opioid Withdrawal Syndrome, currently marketed, and Opioid Withdrawal Syndrome emerging therapies • Opioid Withdrawal Syndrome Market Dynamics: Opioid Withdrawal Syndrome market drivers and Opioid Withdrawal Syndrome market barriers • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies • Opioid Withdrawal Syndrome Unmet Needs, KOL's views, Analyst's views, Opioid Withdrawal Syndrome Market Access and Reimbursement To learn more about the key players and advancements in the Opioid Withdrawal Syndrome treatment landscape, visit the Opioid Withdrawal Syndrome Market Analysis Report Table of Contents 1. Opioid Withdrawal Syndrome Market Report Introduction 2. Executive Summary for Opioid Withdrawal Syndrome 3. SWOT analysis of Opioid Withdrawal Syndrome 4. Opioid Withdrawal Syndrome Patient Share (%) Overview at a Glance 5. Opioid Withdrawal Syndrome Market Overview at a Glance 6. Opioid Withdrawal Syndrome Disease Background and Overview 7. Opioid Withdrawal Syndrome Epidemiology and Patient Population 8. Country-Specific Patient Population of Opioid Withdrawal Syndrome 9. Opioid Withdrawal Syndrome Current Treatment and Medical Practices 10. Opioid Withdrawal Syndrome Unmet Needs 11. Opioid Withdrawal Syndrome Emerging Therapies 12. Opioid Withdrawal Syndrome Market Outlook 13. Country-Wise Opioid Withdrawal Syndrome Market Analysis (2020–2034) 14. Opioid Withdrawal Syndrome Market Access and Reimbursement of Therapies 15. Opioid Withdrawal Syndrome Market Drivers 16. Opioid Withdrawal Syndrome Market Barriers 17. Opioid Withdrawal Syndrome Appendix 18. Opioid Withdrawal Syndrome Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
